Interleukin 38 as a Biomarker for Metabolic Syndrome in Psoriatic Patients
NCT ID: NCT05076812
Last Updated: 2021-10-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
96 participants
OBSERVATIONAL
2021-10-31
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1 (Psoriasis only)
contains 24 psoriatic patients, Psoriasis Area Severity Index will be measured, also waist circumference, body mass index, blood pressure, fasting blood glucose and fasting lipid profile and finally: plasma level of interleukin 38
measure plasma level of interleukin 38 by ELISA kit
draw 5 ml of venous blood into EDTA tubes and centrifuged then plasma is separated for test
Group 2 (Psoriasis and metabolic syndrome)
contains 24 psoriatic patients with metabolic syndrome. Psoriasis Area Severity Index will be measured metabolic syndrome is diagnosed after measuring waist circumference, body mass index, blood pressure, fasting blood glucose and fasting lipid profile finally: plasma level of interleukin 38
measure plasma level of interleukin 38 by ELISA kit
draw 5 ml of venous blood into EDTA tubes and centrifuged then plasma is separated for test
Group 3 (Metabolic syndrome only)
contains 24 patients with metabolic syndrome only. full dermatological examination to exclude psoriasis and other inflammatory skin disorders metabolic syndrome is diagnosed after measuring waist circumference, body mass index, blood pressure, fasting blood glucose and fasting lipid profile finally: plasma level of interleukin 38
measure plasma level of interleukin 38 by ELISA kit
draw 5 ml of venous blood into EDTA tubes and centrifuged then plasma is separated for test
Group 4 (Healthy Controls)
contains 24 healthy control subjects full dermatological examination to exclude psoriasis and other inflammatory skin disorders metabolic syndrome is excluded after measuring waist circumference, body mass index, blood pressure, fasting blood glucose and fasting lipid profile finally: plasma level of interleukin 38
measure plasma level of interleukin 38 by ELISA kit
draw 5 ml of venous blood into EDTA tubes and centrifuged then plasma is separated for test
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
measure plasma level of interleukin 38 by ELISA kit
draw 5 ml of venous blood into EDTA tubes and centrifuged then plasma is separated for test
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yomna Abdo Abdellatif
resident doctor in dermatology venereology and andrology department in sohag university hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
yomna a abdellatif, MBBCH
Role: PRINCIPAL_INVESTIGATOR
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
wafaa m abdel-magid, asst prof
Role: CONTACT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Soh-Med-21-09-02
Identifier Type: -
Identifier Source: org_study_id